The estimated Net Worth of Dirk G. Brockstedt is at least 2.38 百万$ dollars as of 5 January 2024. Dirk Brockstedt owns over 898 units of RAPT Therapeutics stock worth over 53,693$ and over the last 9 years he sold RAPT stock worth over 1,528,348$. In addition, he makes 797,134$ as Chief Scientific Officer at RAPT Therapeutics.
Dirk has made over 49 trades of the RAPT Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 898 units of RAPT stock worth 20,456$ on 5 January 2024.
The largest trade he's ever made was selling 65,223 units of RAPT Therapeutics stock on 15 December 2017 worth over 528,959$. On average, Dirk trades about 6,936 units every 48 days since 2015. As of 5 January 2024 he still owns at least 27,820 units of RAPT Therapeutics stock.
You can see the complete history of Dirk Brockstedt stock trades at the bottom of the page.
Dr. Dirk Brockstedt Ph.D. serves as Chief Scientific Officer of the Company.D. was Senior Vice President of the Company. Since October 2017, he has also served as Executive in Residence at ShangPharma Innovation Inc., a healthcare investment company. From September 2011 to December 2017, he served as Senior Vice President of Research and Development and most recently as Executive Vice President of Research and Development at Aduro Biotech, Inc., a biopharmaceutical company. Dr. Brockstedt served as Director of Research at Anza Therapeutics, Inc. from 2007 to 2009, Director of Immunology at Cerus Corporation from 2002 to 2007 and Senior Research Scientist at Aventis Pharmaceuticals, Inc. from 1999 to 2002, each a biopharmaceutical company. Prior to that he was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. Dr. Brockstedt received a Ph.D. in Microbiology from the University of Kiel (graduate work performed at Stanford University) and an M.S. in Microbiology from the University of Kiel.
As the Chief Scientific Officer of RAPT Therapeutics, the total compensation of Dirk Brockstedt at RAPT Therapeutics is 797,134$. There are 2 executives at RAPT Therapeutics getting paid more, with Rodney Young having the highest compensation of 2,296,220$.
Dirk Brockstedt is 51, he's been the Chief Scientific Officer of RAPT Therapeutics since 2019. There are 12 older and 2 younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.
Dirk's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at RAPT Therapeutics have traded over 79,325,123$ worth of RAPT Therapeutics stock and bought 4,298,405 units worth 48,553,258$ . The most active insiders traders include Peter Svennilson、David V Goeddel、Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of 127,774$. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth 20,456$.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics executives and other stock owners filed with the SEC include: